Company news

Cel-Sci Corporation news in 2026

Cel-Sci Corporation's news releases, calls and decks from 2026, newest first.

View company

CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival

October 26, 2026

CEL-SCI Reports Fiscal Third Quarter 2026 Results

August 17, 2026

Cel-Sci: Fiscal Q3 Earnings Snapshot

August 14, 2026

CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

July 13, 2026

CEL-SCI Announces Closing of Offering

June 16, 2026

CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

June 16, 2026

CEL-SCI Corporation Announces Pricing of Offering

June 14, 2026

CEL-SCI Reports Fiscal Second Quarter 2026 Results

May 18, 2026

Cel-Sci: Fiscal Q2 Earnings Snapshot

May 15, 2026

CEL-SCI Corporation Announces Pricing of Public Offering

May 11, 2026

CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia

May 11, 2026

CEL-SCI Reports Fiscal First Quarter 2026 Results

February 18, 2026

Cel-Sci: Fiscal Q1 Earnings Snapshot

February 17, 2026

Decks in 2026